OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-03-31-accounts

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society Unaudited Financial Statements Year Ended 31 March 2025

Company Registration Number 06996552 Charity Registration Number 1136972

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Financial Statements

Year Ended 31 March 2025

Contents Page
Trustees' Report 1
Independent Examiner’s Report 4
Statement of Financial Activities 5
Balance Sheet 6
Notes to the Financial Statements 7

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Trustees’ Report (continued)

Year Ended 31 March 2025

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2025.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

  1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and

  2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

Activities and achievements aligned to the charity’s aims for the year 2024/25

3

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Trustees’ Report (continued)

Year Ended 31 March 2025

innovation and research. The conference programme and abstracts were held in a handheld application for ease before and during the conference. Last year we aimed to increase the number of sessions where chose abstracts presented in breakout sessions and the plenary sessions.

SACT Members Interest Group:

Acute Oncology Members Interest Group:

Personalised Cancer Care Members Interest Group:

Radiotherapy Members Interest Group :

Haematology Members Interest Group:

Research Members Interest Group:

4

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Trustees’ Report (continued)

Year Ended 31 March 2025

Education Competency and Capability:

Growing forums:

Work continues to take requests from members for forum activity:

Practice Educator Forum:

Champions Forum:

Lead Nurse Forum:

Young and Early Career Forum (YECC):

Partnership working: .

5

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Trustees’ Report (continued)

Year Ended 31 March 2025

Organisational Structure

The Board has five executive officers: President, President Elect, Past President, Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees receive induction into their role on the Board.

Assessment of going concern

The charity’s income is reliant on sponsorship from UKONS Partners. Income for 24/25 was reduced from the previous year but not significantly. It continues to be unpredictable for some partners and their budget constraints. The board maintain a cautious approach and these factors have been considered in budgeting resources for the next financial year.

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:

Karen Campbell (President) Mary Tanay (President Elect) Mark Foulkes (Past President) Lyndel Moore (Treasurer) Jo Bird (Secretary - appointed 4 December 2024) Kay Bell (resigned 4 December 2024) Rachel Bryce (appointed 4 December 2024) Naomi Clatworthy Jane Ewang (appointed 4 December 2024) Ruth Hammond Nicola Jones (appointed 4 December 2024) Nalayini Kumaralingam (resigned 5 December 2024) Bethany Maynard (appointed 4 December 2024) Barry Quinn Rosemary Roberts (resigned 4 December 2024) Constance Rowell Linda Sherwood Tracy Wilson Debbie Wightman (resigned 4 December 2024)

Reserves

The Trustees plan to retain a modest level of reserves as a contingency fund against future demands on the charity’s resources.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors [aren …………………………… BA8F1726C53B49B...by: Dr Karen Campbell Director

03 September 2025 Approved on ……………………………………2025

6

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Independent Examiner’s Report to the Trustees

Year Ended 31 March 2025

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2025.

Responsibilities and basis of report

As the charity’s trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (“the 2006 Act”).

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner’s statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

  1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a ‘true and fair view’ which is not a matter considered as part of an independent examination; or

  4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

[fartSigned342D60FB7F7A405...by: Kobbs

Martin Hobbs BSc ACA

Francis Clark LLP Chartered Accountants Sigma House Oak View Close Edginswell Park Torquay TQ2 7FF

04 September 2025 Date: ……………………………..2025

7

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Statement of Financial Activities (incorporating an Income and Expenditure Account)

Year Ended 31 March 2025

Unrestricted Restricted Total Total
Funds Funds 2025 2024
£ £ £ £
Income from:
Partnership income 130,500 - 130,500 147,042
Board activity 5,885 - 5,885 19,235
Donations - - - 1,408
Grants - - - 40,000
Other income - - - 16,667
––––—— ––––—— ––––—— ––––——
Total 136,385 - 136,385 224,352
––––—— ––––—— ––––—— ––––——
Expenditure on:
BJN Awards 27 - 27 277
CASCADE workshop - - - 2,111
Covid 19 and Cancer book - - - 11,402
Personalised Cancer Care Book - - - 4,000
Pocketbook of Cancer Care Nursing - - - 8,333
Cytotoxic Drug Exposure Research Grant 13,348 - 13,348 -
SACT passport project 16,244 16,244 58,435
EBN Health book - - - 2,917
Palliative care booklet - - - -
EONS membership fee 835 - 835 875
ISNCC membership fee
494
- 494 248
Annual conference 19,112 - 19,112 38,122
Board meetings – Travel and subsistence 6,464 - 6,464 7,784
Other conferences 927 - 927 14,634
Entertaining/other meetings 2,116 - 2,116 14,346
MIGs 5,509 - 5,509 8,202
Administrative support 21,600 - 21,600 26,760
Secretarial services 15,000 - 15,000 15,000
Legal and professional 795 - 795 660
Stationery and admin - - - 186
Website and social media 8,091 - 8,091 7,043
Accounting fees 10,744 - 10,744 10,320
Insurance 1,068 - 1,068 985
Irrecoverable VAT 8,174 - 8,174 10,997
Grants BMS AOS 484 - 484 36,485
Purchases 325 - 325 10,734
––––—— ––––—— ––––—— ––––——
Total 131,357 - 131,357 290,856
––––—— ––––—— ––––—— ––––——
Net income/(expenditure) 5,028 - 5,028 (66,504)
Total funds brought forward 122,303 - 122,303 188,807
––––—— ––––—— ––––—— ––––——
Total funds carried forward 127,331 - 127,331 122,303
══════ ══════ ══════ ══════

All of the incoming resources of the charity for the comparative year are unrestricted. All of the above results are derived from continuing activities. All gains and losses recognised in the year are included above. The result for the year for Companies Act purposes is equivalent to the net income / (expenditure).

8

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Balance Sheet

31 March 2025

Notes 2025 2024
£ £
Current assets
Debtors 4 55,827 53,095
Cash at bank and in hand 189,265 151,808
––––—— ––––——
245,092 204,903
Liabilities
Creditors falling due within one year 5 (117,761) (82,600)
––––—— ––––——
Total assets less current liabilities 127,331 122,303
══════ ══════
Unrestricted funds 6 127,331 122,303
Restricted funds 6 - -
––––—— ––––——
Total funds 127,331 122,303
══════ ══════

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act.

These financial statements were approved and signed by the trustees and authorised for issue on …………………………. 2025, and are signed on their behalf by: 03 September 2025

[aren ……………………………….. BA8F1726C53B49B...by: Karen Campbell

Director

Company Registration Number: 06996552

9

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Notes to the Financial Statements

Year Ended 31 March 2025

1 Accounting Policies

Basis of accounting

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation of financial statements and assessment of going concern

The financial statements have been prepared under the historical cost convention and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The UK Oncology Nursing Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The functional and presentational currency of these financial statements is sterling.

The trustees consider that there are no material uncertainties about the Charity’s ability to continue as a going concern.

b) Income

Income is recognised when the charity has entitlement to funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Capital grants receivable are credited to the SOFA as they become receivable and are treated as restricted funds. The depreciation on the assets to which the grants relate is charged against these funds.

c) Fund accounting

Unrestricted funds are funds available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds received which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes.

d) Expenditure

Expenditure is recognised once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure includes irrecoverable VAT.

e) Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. The company holds the following financial instruments, all of which are considered to be basic:

10

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Notes to the Financial Statements

Year Ended 31 March 2025

2 Related Party Transactions

During the year travel expenses of £3,270 were reimbursed to 12 trustees (2024: £11,919 to 13 trustees).

3 Company Limited by Guarantee

The company is limited by guarantee and has no share capital. In the event of a winding-up, the liability of the members is limited to £1 each. The Charity is incorporated in England and Wales. The address of its registered office is: Office 605, Albert House, 256-260 Old St, London EC1V 9DD.

4 Debtors

Creditors: amounts falling due within one year
Trade debtors
Prepayments and accrued income
VAT
Accruals and deferred income
VAT payable
Other creditors
2025
£
2024
£
49,294
40,702
6,533
5,599
-
6,794
55,827
53,095
2025
£
2024
£
106,905
82,600
10,856
-
-
-
117,761
82,600

5 Creditors: amounts falling due within one year

6 Analysis of movement in funds

Total unrestricted funds Balance at
1 April
2024
£
Incoming
resources
£
Resources
expended
£
Balance at
31 March
2025
£
122,303
136,385
(131,357)
127,331
122,303
136,385
(131,357)
127,331

11

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Notes to the Financial Statements

Year Ended 31 March 2025

6 Analysis of movement in funds (continued)

Prior year analysis of movement in funds

Total unrestricted funds
Restricted funds:
Gilead
BMS
AOS education grant
EBN book grant
Balance at
1 April
2023
£
Incoming
resources
£
Resources
expended
£
Balance at
31 March
2024
£
183,660
184,352
(245,709)
122,303
-
5,000
(5,000)
-
-
35,000
(35,000)
-
2,230
-
(2,230)
-
2,917
-
(2,917)
-
188,807
224,352
(290,856)
122,303

The Gilead grant represents funds to support healthcare professionals to attend the UKONS 2023 conference.

The BMS AOS grant represents funds raised towards the development of acute oncology service telephone triage E-learning modules

The AOS education grant represents funds raised for the development of a digital friendly format for UKONS guidance for assessment of patients.

The EBN book grant represents funds raised for the writing and publication of a reference book entitled “Fundamentals of Cancer Care”.

The restricted funds are all held as cash at bank and in hand.

12